Journal
ANALYTICAL CHEMISTRY
Volume 94, Issue 46, Pages 16213-16221Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.analchem.2c03765
Keywords
-
Categories
Funding
- Natural Science Foundation of Guangdong Province
- Science and Technology Projects in Guangzhou
- [2022 A 1 5 1 5 0 1 0 4 8 2]
- [2022A1515010373]
- [2020A1515011066]
- [202102020145]
Ask authors/readers for more resources
In this study, a novel MRI contrast agent ZGMP was synthesized, which can produce enhanced MRI signals through a cascade reaction in early AD mice, providing a convenient way for MRI diagnosis.
Brain glucose is an important biomarker of Alzheimer's disease (AD) and has a high specificity especially for early AD. Activatable magnetic resonance imaging (MRI) contrast agents (CAs) serve as a robust technology in the early diagnosis of many diseases; however, there is a lack of glucose-specific MRI CAs. To address this issue, in this work, we synthesized a novel MRI CA (ZIF-8/GOx@MnO2@PEG, ZGMP) that consists of porous zeolitic imidazolate framework-8 (ZIF-8) attached with glucose oxidase (GOx) and modified by MnO2 and PEG. The cascade reaction of brain glucose with ZGMP could result in the production of Mn(II) and an enhanced MRI signal. An early AD mouse model was constructed through injection of the A beta 42 oligomer into the parenchyma of mice and utilized to verify the brain glucose activated MRI of ZGMP. The results indicated a higher glucose uptake in early AD mice compared to that in normal mice, with an obviously enhanced T1WI at the region of interest. This work gets rid of the need for a specific scanning sequence for glucose MRI, paving a convenient way for MRI diagnosis of early AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available